Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Mapping SCA1 regional vulnerabilities reveals neural and skeletal muscle contributions to disease
Lisa Duvick, … , Michael D. Koob, Harry T. Orr
Lisa Duvick, … , Michael D. Koob, Harry T. Orr
Published March 21, 2024
Citation Information: JCI Insight. 2024;9(9):e176057. https://doi.org/10.1172/jci.insight.176057.
View: Text | PDF
Research Article Neuroscience

Mapping SCA1 regional vulnerabilities reveals neural and skeletal muscle contributions to disease

  • Text
  • PDF
Abstract

Spinocerebellar ataxia type 1 (SCA1) is a fatal neurodegenerative disease caused by an expanded polyglutamine tract in the widely expressed ataxin-1 (ATXN1) protein. To elucidate anatomical regions and cell types that underlie mutant ATXN1-induced disease phenotypes, we developed a floxed conditional knockin mouse (f-ATXN1146Q/2Q) with mouse Atxn1 coding exons replaced by human ATXN1 exons encoding 146 glutamines. f-ATXN1146Q/2Q mice manifested SCA1-like phenotypes including motor and cognitive deficits, wasting, and decreased survival. Central nervous system (CNS) contributions to disease were revealed using f-ATXN1146Q/2Q;Nestin-Cre mice, which showed improved rotarod, open field, and Barnes maze performance by 6–12 weeks of age. In contrast, striatal contributions to motor deficits using f-ATXN1146Q/2Q;Rgs9-Cre mice revealed that mice lacking ATXN1146Q/2Q in striatal medium-spiny neurons showed a trending improvement in rotarod performance at 30 weeks of age. Surprisingly, a prominent role for muscle contributions to disease was revealed in f-ATXN1146Q/2Q;ACTA1-Cre mice based on their recovery from kyphosis and absence of muscle pathology. Collectively, data from the targeted conditional deletion of the expanded allele demonstrated CNS and peripheral contributions to disease and highlighted the need to consider muscle in addition to the brain for optimal SCA1 therapeutics.

Authors

Lisa Duvick, W. Michael Southern, Kellie A. Benzow, Zoe N. Burch, Hillary P. Handler, Jason S. Mitchell, Hannah Kuivinen, Udaya Gadiparthi, Praseuth Yang, Alyssa Soles, Carrie A. Sheeler, Orion Rainwater, Shannah Serres, Erin B. Lind, Tessa Nichols-Meade, Yun You, Brennon O’Callaghan, Huda Y. Zoghbi, Marija Cvetanovic, Vanessa C. Wheeler, James M. Ervasti, Michael D. Koob, Harry T. Orr

×

Figure 4

Progression of kyphosis pathology in f-ATXN1146Q/2Q mice is corrected with deletion of ATXN1146Q in skeletal muscle.

Options: View larger image (or click on image) Download as PowerPoint
Progression of kyphosis pathology in f-ATXN1146Q/2Q mice is corrected wi...
(A–D) CT scan image of f-ATXN1146Q/2Q, f-ATXN1146Q/2Q;Nestin-Cre, f-ATXN1146Q/2Q;ACTA1-Cre, and WT-Atxn12Q/2Q mice at 20 and 50 weeks. Scale bar: 10 mm. (E and F) Kyphosis image calculation and kyphotic index at 50 weeks, using 1-way ANOVA, compared with WT-Atxn12Q/2Q with Dunnett’s post hoc test. ***P < 0.001 and ****P < 0.0001. (G) Assessment of grip strength for f-ATXN1146Q/2Q and f-ATXN1146Q/2Q;ACTA1-Cre compared with WT-Atxn12Q/2Q and WT-Atxn12Q/2Q;ACTA1-Cre mice at 18 weeks of age. (H) Assessment of grip strength for f-ATXN1146Q/2Q and f-ATXN1146Q/2Q;Nestin-Cre compared with WT-Atxn12Q/2Q and WT-Atxn12Q/2Q;Nestin-Cre mice at 18 weeks of age. One-way ANOVA with Tukey’s post hoc test were performed for all. *P < 0.05, **P < 0.01, and ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts